Vaccine Programs

Sci-B-Vac™

HBV

Hepatitis B
Approved

Sci-B-Vac is a commercial stage hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus and is free of any next-generation adjuvant. Sci-B-Vac offers rapid onset of protection, high levels of anti-HBV antibodies, and can be administered at lower doses than competing HBV vaccines. Sci-B-Vac is approved in Israel and in 14 other countries and has demonstrated a favorable safety and efficacy profile in over 300,000 patients. Learn more about Sci-B-Vac >>

Vaccine Candidates

Discovery

Preclinical

Phase I

CMV

Cytomegalovirus
Phase I

Phase I

85%

GBM

Glioblastoma multiforme
Preclinical

Preclinical

50%

MB

Medulloblastoma
Preclinical

Preclinical

45%

Zika virus
Discovery

Discovery

30%

RSV

Respiratory syncytial virus
Discovery

Discovery

30%